...Sirion began a Phase III trial of topical ST-603. Laboratorios Sophia granted Sirion rights to develop and...
...the U.S. last year (see BioCentury, July 31, 2006). Sirion Therapeutics Inc. , Tampa, Fla. Laboratorios Sophia S.A. de C.V....

...containing difluprednate to treat inflammation following ocular surgery. Sirion has U.S. rights to ST-603 from Laboratorios Sophia...

...inflammation in the first half of next year. Sirion has U.S. rights to ST-603 from Laboratorios Sophia S.A. de C.V....

...inflammation in the first half of next year. Sirion has U.S. rights to ST-603 from Laboratorios Sophia...

...to treat age-related macular degeneration (AMD) this year. Sirion has U.S. rights to ST-603 from Laboratorios Sophia S.A. de C.V....

...to treat age-related macular degeneration (AMD) this year. Sirion has U.S. rights to ST-603 from Laboratorios Sophia...

...first half of 2007. Financial terms were not disclosed. Sirion Therapeutics Inc. , Tampa, Fla. Laboratorios Sophia S.A. de C.V....

...sustained delivery of genes to the eye. Clear Solutions Biotech Inc. , Stony Brook, N.Y. Laboratorios Sophia S.A. de C.V....